Name: establishment and characterization of uti and cauti in a mouse model
Uploaded: 2015-06-23T15:00:00.000+00:00
Duration: 8 min 40 s
Description: Watch this Scientific Journal Video about Establishment and Characterization of UTI and CAUTI in a Mouse Model at JoVE.com

资助这项工作是由ORWH SCOR P50 DK064540提供，RO1 DK 051406，RO1 AI 108749-01，F32 DK 101171，和F32 DK 104516-01。

伦理声明:华盛顿大学动物研究委员会批准所有的鼠标感染和程序的协议号20120216，这是批准2013年1月11日，截止2016年1月11日部分。整体护理的动物是有照顾和实验动物从国家研究委员会和美国农业部的动物保健资源指南的指导使用一致的。安乐死程序与一致"的动物版本2013的安乐死AVMA准则。" 1.统一企业UTI协议，接种针准备（图S1） <ol><li>卸下地下30针帽。线程大约1英寸PE10管到针的轴。一夜之间紫外线消毒针头组件。插管针可以无限期储存在无菌培养皿。 </li></ol> 2.统一企业细菌接种准备<ol><li>准备UTI89接种（开始之前接种72小时化天） <ol><li>连胜UTI89到从冷冻股票的LB（卢里亚BERTANI）琼脂平板上。孵育过夜，在37℃。选择一个菌落，接种到10ml的LB在125毫升瓶中。在37℃下放置24小时，静态。 </li><li>接种10微升过夜培养到10ml的LB的在一个新125毫升烧瓶另外24小时，在37℃，静态。 </li><li>传输3毫升（将根据应变和所需的接种量有所不同）无菌1.5毫升管和离心在7000 XG 3分钟，悬浮颗粒在1X PBS离心第二次。重悬细菌沉淀在1ml的1×PBS。 </li></ol></li><li>测量细菌的光密度，并调整浓度至所需要的接种物密度。所用的接种物的标准浓度为10 7细菌;然而，这可能会发生变化，由于该研究的设计。 </li></ol> 3.细菌接种<ol><li>清洁用70％乙醇和c工作站在用吸水纸面积（或使用无菌流罩）。 </li><li>绘制高达0.9毫升制备的细菌接种物加到1毫升（TB）的注射器（去除气泡）。附加准备无菌接种针管PE10，到含接种注射器，无菌然后修剪聚乙烯管材。 注:保持1毫米管的针的顶端的上方，以避免刺穿囊。 </li><li>切一个1英寸的方片封口膜，并把手术润滑剂的DAB（一毛钱的大约尺寸）之上。 </li><li>通过把它们放在一个32盎司的玻璃罐内含有茶输液球泡用3毫升异氟醚或蒸发器室的棉球麻醉雌性C3H / HeN小鼠（以下生产协议），直到不省人事，但仍正常呼吸（1呼吸/秒） 。 注意:有些IACUC委员会不批准使用一个罐子或蒸发器。请按照你的机构的IACUC委员会的指示。 注:如果玻璃瓶用茶球和/或鼻锥与异氟醚soakd棉球时，动物必须要仔细观察，以避免过量麻醉而死亡。用一个蒸发器和麻醉室的优点在于，它提供受控的异氟烷施用，避免意外过量。注意:异氟醚是一种吸入麻醉剂。用在通风良好的地方，并尽量减少吸入。 </li><li>从罐子/汽化器除去小鼠并将其放置在其上的纸背巾和蔓延的腿。 </li><li>覆盖鼠标与鼻锥鼻或50毫升锥形管，用棉球含有少量（大约1-2毫升（连接到用来提供受控异氟烷剂量是配备在某些汽化器单元的蒸发器的管） ）异氟醚。 </li><li>轻轻地悸膀胱排尿诱导并确保空隙膀胱。擦拭用100％乙醇擦拭尿道周围区域。第一轻拍接种针/注射器，点，进手术润滑剂。 </li><li>通过经尿道插入接种针，约12毫米，并且压下针筒柱塞轻轻分配接种入膀胱轻轻（10微升/秒）接种每个小鼠用50μl细菌溶液。取出接种针从鼠标。 注:接种时开始接种时尿道口立即返回指示不正确或不完整的插入针头。 </li><li>从鼻锥取出鼠标，并返回到它的笼子。每只小鼠重复步骤3.3-3.8。当/如果切换接种条件/株，处理在批准的锐器容器的注射器和针头接种，并重新开始步骤3.2。 注:接种肾盂肾炎生物一般不会引起严重的疼痛症状。然而，在少数情况下，给予大剂量的病原体可能引起发热，减少食物和水的摄入量和行为异常。一个nimal健康应在整个实验进行监测。如果公开痛症状是通知，止痛剂，如丁丙诺啡（0.05-0.1毫克/千克皮下注射），都可以应用。程序应根据每个机构的IACUC。 </li></ol> 4.确定细菌负担<ol><li>准备个单独的5 mL管每个膀胱和肾脏对收获。添加的1X PBS /管/鼠标膀胱1毫升收获。添加0.8毫升1X PBS /管/双鼠标肾脏收获。标记每个管以对应于一个给定的鼠标。制备含有180微升的1×PBS中的各孔对1:10连续稀释在96孔板。 </li><li>清洁用70％乙醇的工作区，还包括与吸收性盖或纸巾的区域。 </li><li>麻醉小鼠异氟醚（见步骤3.4），直到鼠标停止呼吸约1分钟，然后将其放置在吸收盖或纸巾。 euthana的其它方法SIA还接受IACUC委员会，如二氧化碳，可被取代的异氟醚过量。 </li><li>通过快速颈椎脱位，由抑制所述颈部在头部的基部和拉动尾部水平远离身体，直到发生错位的牺牲小鼠。 注意:大多数IACUC委员会需​​要安乐死和颈椎脱位的辅助装置是一个常用的方法。然而，其它方法可用于如经IACUC委员会。 </li><li>将死老鼠在它的后面，并喷洒70％的乙醇在腹部。解剖小鼠，收获膀胱和肾脏，在为了尽量减少从血液以下肾脏解剖潜在污染。独立广场机关到准备好的5毫升管含有1x PBS（见步骤4.1）。 注:使用不同的剪刀为外部解剖和器官摘取，以减少污染。 </li><li>点击管，以确保器官在T他的1X PBS。每只小鼠重复步骤4.3-4.5。清洁剪刀和在每个小鼠后70％的乙醇钳子。 </li></ol> 5.细菌恢复<ol><li>均质收获膀胱和肾脏中5毫升管子用组织匀浆器，15秒每肾和每囊30秒。在1×PBS中，70％的乙醇和样品之间的1×PBS冲洗顺序均化。 </li><li>使串行1:10稀释出来至10 -8和板在LB琼脂平板各稀释为CFU（菌落形成单位）。孵育所述板在37℃过夜并计数菌落第二天。 </li></ol> 6. IBC枚举<ol><li>无菌取出膀胱，并将其放置在1×PBS中的6孔板用硅氧烷底部。板可使用有机硅弹性体包和浇注大约1cm硅氧烷的每个孔中来制备，见生产商的说明。切用剪刀膀胱一半。 </li><li>用小金属针轻轻的张开BLAD明镜使膀胱内腔朝上。确保将销在膀胱部分的最外边缘，以确保尿路上皮的最大量被暴露。 </li><li>张开后，轻轻用1X PBS洗一次膀胱。通过吸管取出1X PBS。通过加入足够的3％多聚甲醛，以覆盖整个叉开膀胱修复膀胱。注意:多聚甲醛有致癌性。适当的防护用品，包括手套，应该在任何时候都可以穿。处置应遵循机构准则。 </li><li>在室温下孵育1小时。删除多聚甲醛溶液。与1X PBS洗一次。 </li><li>与LacZ的洗涤液（2毫米氯化镁2，0.01％脱氧胆酸钠和0.02％诺乃-1X p40in PBS）三次，每洗5分钟，洗净。 </li><li>除去洗涤溶液，并添加足够的LacZ染色（9.5毫升LacZ的洗涤溶液中加入0.4ml 25mg / ml的X-gal的和0.1ml的100mM K-亚铁氰化物/ K - 铁氰化物），以覆盖所述囊。孵育在30℃overniGHT避光。 </li><li>从孵化器中取出水囊张开观察中型散货箱，作为与可视化解剖范围，40-60X倍率显示为蓝色的泪点。 注:有时，鼠标可能小便前尿道下管的位置。在这种情况下，等待15-20分钟尝试再次收集尿液之前。 </li></ol> 7.收集尿液的细菌尿CFU枚举（不适用于CAUTI） <ol><li>收集尿液前或后感染握住尾巴，并把它放在平坦的表面升高（鼠笼顶部）轻轻地抑制鼠标。 </li><li>保持无菌的1.5mL管中鼠标下尿道。轻轻按压在小鼠背部的尾部附近向下施加压力，以膀胱。赶上尿1.5 ml管。 </li><li>使串行1时10稀释出10-7和板每个稀释适当LB。孵育所述板在37℃过夜并计数菌落第二天。 </li></ol> 8. CAUTI示范协议，导管针准备CAUTI模型（图S2） <ol><li>卸下地下30针帽。切7mm的一块PE10管材和5mm一块硅胶管，如RenaSIL的。螺纹与PE10管针，直到管顶住针的基部。 </li><li>然后馈送5mm的片上含PE10针。 UV消毒隔夜针组件。 注:当加载硅胶管，留下大约1mm过去针尖延长管。 </li></ol> 9. E. OG1RF 粪细菌接种物制备方法<ol><li>制备OG1RF接种开始之前接种一天48小时。条纹OG1RF到从冷冻的储存在BHI（脑心脏浸液）板。 </li><li>选择一个菌落，接种于10ml BHI并在37℃成长吧静态18小时。离心培养并在1ml体积无菌的1×PBS的洗涤沉淀（3次）。 </li><li>悬浮细菌沉淀到1X PBS。测量细菌光密度和浓度调整到所需的接种量。所用的接种物的标准浓度为10 7;然而，这可能会发生变化，由于该研究的设计</li></ol> 10.导管植入<ol><li>清洁用70％乙醇的工作站，并盖上一个吸收覆盖的区域（或使用无菌流罩）。 </li><li>连接导管针到空的1毫升（TB）的注射器。切一个1英寸的方片封口膜，并把手术润滑剂的DAB（一毛钱的大约尺寸）之上。 注:两种不同的针被用于在导管的沉积和对接种到最小偶然接种由于所需导管植入所述机械操纵。这还允许制备较少接种针的便利性。 </li><li>通过把它们放在一个32盎司的玻璃罐内含有茶麻醉C57BL / 6小鼠-infuser球浸在3毫升异氟醚或蒸发器室的棉球（以下生产协议），直到不省人事，但仍正常呼吸（1呼吸/秒）。 </li><li>然后把鼠标放在其在纸巾上，并回传到腿部。覆盖鼠标与鼻锥或50ml锥形管与含有少量（大约1-2毫升）的异氟烷棉球的鼻子。 注意:异氟醚是一种吸入麻醉剂。用在通风良好的地方，并尽量减少研究员吸入。 </li><li>轻轻地悸膀胱排尿诱导并确保空隙膀胱。擦拭尿道周围区，配有100％的乙醇擦拭。 </li><li>消毒与使用棉尖涂药10％聚维酮碘溶液尿道周围区域。第一轻拍接种针/注射器，点，进入手术润滑剂。 注:Povidine碘被用于导管植入，这是比醇更强无菌溶液。导管植入需要更多的机械操纵插入导管，从而污染更大的潜力。 </li><li>将导管插入尿道口。一旦进入，使用镊子推（7毫米PE10）长片向膀胱，从而推动（5毫摩硅）小导管并沉积到膀胱。取出针，用7毫米的管线还连着，立即执行。 </li></ol> 11.细菌接种<ol><li>按照细菌接种协议第3条，用准备好的接种从9节从鼻锥取出鼠标，并返回到它的笼子</li></ol> 12.在牺牲的每一个时间点<ol><li>准备5毫升管膀胱和肾脏（对于机关按照步骤4.1）和1.5毫升离心管的导管。加入1毫升1×PBS到1.5毫升Eppendorf管用于导管样本</li><li>按照步骤4.3至4.5。解剖鼠标，收获膀胱，肾脏和导管，解放军独立地CING组织成含有1x PBS中，导管进入1.5毫升的Eppendorf（见步骤12.1）5毫升管中。 注:使用不同的剪刀为外部解剖和器官摘取和导管恢复，以减少污染</li><li>然后按照步骤4.6。 </li></ol> 13.细菌恢复<ol><li>对于机关，按照步骤5.1和5.2。细菌回收从导管，涡旋以最大速度为30秒，超声处理导管样品用5分钟的水浴超声，然后涡旋以最大速度进行另外30秒。 </li><li>使串行1:10稀释出10-8和板每个稀释度对BHI板CFU枚举。孵育所述板在37ºC过夜并计数菌落第二天。 </li></ol>

作者宣称，他们有没有竞争的财务权益。

单纯性社区获得性尿路感染是一种常见的和昂贵的感染占每年46几万元的初级保健访问。此外，CAUTIs是一种常见的医疗获得性感染，已成为极其昂贵的医疗保健提供商医疗保险和医疗补助服务中心不再报销提供商用于治疗从医院获得45 CAUTI会带来额外的成本。 UTI，既单纯性膀胱炎和CAUTI的小鼠模型中，在这些协议中描述提供了宝贵的工具用于理解所必需的启动，维持和调节的几种?...

An erratum was issued for: <a href="https://www.jove.com/video/52892/establishment-and-characterization-of-uti-and-cauti-in-a-mouse-model">Establishment and Characterization of UTI and CAUTI in a Mouse Model</a>. The Protocol section has been updated.
The ethics statement has been updated from:
Ethics statement: The Washington University Animal Studies Committee approved all mouse infections and procedures as part of protocol number 20120216, which was approved 01/11/2013 and expires 01/11/2016. Overall care of the animals was consistent with The guide for the Care and Use of Laboratory Animals from the National Research Council and the USDA Animal Care Resource Guide. Euthanasia procedures are consistent with the &#8220;AVMA guidelines for the Euthanasia of Animals 2013 edition.&#8221;
to:
Ethics statement: The Washington University Animal Studies Committee approved all mouse infections and procedures as part of protocol number 20150226, which expires 12/10/2018. Overall care of the animals was consistent with The Guide for the Care and Use of Laboratory Animals from the National Research Council and the USDA Animal Care Resource Guide. Euthanasia procedures are consistent with the &#8220;AVMA guidelines for the Euthanasia of Animals 2013 edition.&#8221;
Step 3 has been updated from:
3. Bacterial Inoculation
<ol>
	<li>Clean the workstation with 70% ethanol and cover area with absorbent paper (or use sterile flow hood).</li>
	<li>Draw up to 0.9 ml of the prepared bacterial inoculum into a 1 ml (TB) syringe (remove air bubbles). Attach a prepared sterile inoculation needle with PE10 tubing, onto the syringe containing the inoculum, then sterilely trim the polyethylene tubing. 
	NOTE: Leave 1 mm of tubing above the tip of the needle to avoid puncturing the bladder.</li>
	<li>Cut a 1 inch square piece of parafilm and put a dab of surgical lubricant (approximately the size of a dime) on top.</li>
	<li>Anesthetize female C3H/HeN mice by putting them in a 32 ounce glass jar containing a tea-infuser ball with cotton balls soaked with 3 ml of isoflurane or vaporizer chamber (following manufactures protocol) until unconscious but still breathing normally (1 breath/sec). 
	NOTE: Some IACUC committees do not approve the use of a jar or vaporizer. Please follow the indication of the IACUC committee of your institution. 
	NOTE: If glass jar with tea-ball and/or nose cone with isoflurane-soakd cotton balls are used, the animal must be carefully observed to avoid anesthetic overdose and death. The advantage of using a vaporizer and anesthesia chamber is that it provides controlled isoflurane administration that avoids accidental overdoses. CAUTION: Isoflurane is an inhalation anesthetic. Use in a well-ventilated area and minimize inhalation.</li>
	<li>Remove the mouse from the jar/vaporizer and place it on its back on a paper towel and spread the legs.</li>
	<li>Cover the nose of the mouse with a nose cone (a tube connected to the vaporizer that provides a controlled isoflurance dose that comes equipped on some vaporizer units) or 50 ml conical tube with a cotton ball containing a small amount (approximately 1-2 ml) of isoflurane.</li>
	<li>Gently palpitate the bladder to induce urination and ensure a voided bladder. Wipe the periurethral area with 100% ethanol wipe. Dab the inoculation needle/syringe, point first, into the surgical lubricant.</li>
	<li>Inoculate each mouse with 50 &#181;l of the bacteria solution by inserting the inoculation needle transurethrally, approximately 12 mm, and pressing down on the syringe plunger gently to dispense the inoculum into the bladder gently (10 &#181;l/sec). Remove the inoculation needle from the mouse. 
	NOTE: Immediate return of inoculum at the urethral opening when beginning to inoculate indicates improper or incomplete insertion of the needle.</li>
	<li>Remove the mouse from nose cone and return it to its cage. Repeat steps 3.3-3.8 for each mouse. When/if switching inoculum conditions/strains, dispose of the syringe and inoculation needle in an approved sharps container and start again step 3.2.&#160;&#160; 
	NOTE: Inoculation with uropathogenic organisms generally does not cause severe pain symptoms. However, in rare instances, administering large doses of pathogens may cause fever, reduction in food and water intake and abnormal behavior. Animal health should be monitored throughout the experiment. If overt pain symptoms are notice, an analgesic, such as Buprenorphine (0.05&#8722;0.1 mg/kg given subcutaneously), can be applied. Procedures should be in accordance with each institution&#8217;s IACUC.</li>
</ol>
to:
3. Bacterial Inoculation
<ol>
	<li>Clean the workstation with 70% ethanol and cover area with absorbent paper (or use sterile flow hood).</li>
	<li>Draw up to 0.9 ml of the prepared bacterial inoculum into a 1 ml (TB) syringe (remove air bubbles). Attach a prepared sterile inoculation needle with PE10 tubing, onto the syringe containing the inoculum, then sterilely trim the polyethylene tubing. 
	NOTE: Leave 1 mm of tubing above the tip of the needle to avoid puncturing the bladder.</li>
	<li>Cut a 1 inch square piece of parafilm and put a dab of surgical lubricant (approximately the size of a dime) on top.</li>
	<li>Anesthetize female C3H/HeN mice by putting them in a vaporizer chamber (following manufactures protocol) until unconscious but still breathing normally (1 breath/sec). 
	NOTE: Some IACUC committees do not approve the use of a vaporizer. Please follow the indication of the IACUC committee of your institution. 
	CAUTION: Isoflurane is an inhalation anesthetic. Use in a well-ventilated area and minimize inhalation.</li>
	<li>Remove the mouse from the vaporizer and place it on its back on a paper towel and spread the legs.</li>
	<li>Cover the nose of the mouse with a nose cone (a tube connected to the vaporizer that provides a controlled isoflurance dose that comes equipped on some vaporizer units) to maintain anesthetization.</li>
	<li>Gently palpitate the bladder to induce urination and ensure a voided bladder. Wipe the periurethral area with 100% ethanol wipe. Dab the inoculation needle/syringe, point first, into the surgical lubricant.</li>
	<li>Inoculate each mouse with 50 &#181;l of the bacteria solution by inserting the inoculation needle transurethrally, approximately 12 mm, and pressing down on the syringe plunger gently to dispense the inoculum into the bladder gently (10 &#181;l/sec). Remove the inoculation needle from the mouse. 
	NOTE: Immediate return of inoculum at the urethral opening when beginning to inoculate indicates improper or incomplete insertion of the needle.</li>
	<li>Remove the mouse from nose cone and return it to its cage. Repeat steps 3.3-3.8 for each mouse. When/if switching inoculum conditions/strains, dispose of the syringe and inoculation needle in an approved sharps container and start again step 3.2.&#160;&#160; 
	NOTE: Inoculation with uropathogenic organisms generally does not cause severe pain symptoms. However, in rare instances, administering large doses of pathogens may cause fever, reduction in food and water intake and abnormal behavior. Animal health should be monitored throughout the experiment. If overt pain symptoms are notice, an analgesic, such as Buprenorphine (0.05&#8722;0.1 mg/kg given subcutaneously), can be applied. Procedures should be in accordance with each institution&#8217;s IACUC.</li>
</ol>

An erratum was issued for: <a href="https://www.jove.com/video/52892/establishment-and-characterization-of-uti-and-cauti-in-a-mouse-model">Establishment and Characterization of UTI and CAUTI in a Mouse Model</a>. The Protocol section has been updated.

Erratum: Establishment and Characterization of UTI and CAUTI in a Mouse Model

尿路感染（尿路感染）是最常见的细菌感染中的一个，并可以分为基于采集，社区和医院获得性泌尿道感染的机制两类。社区获得性尿路感染常发生在其他方面健康的妇女，研究显示妇女大约50％将具有至少一个UTI在其一生中1。此外，复发是一个重大问题。谁拥有一个初始急性感染的妇女，尽管有适当的抗生素治疗，许多妇女继续有反复发作2具有半年内第二次感染的25-40％的机会。引起这类感染的细菌也日益抗生素有抗药性的进一步混杂的治疗方案3-6。每年UTI影响数以百万计的个人耗资约2.5十亿美元的医疗保健相关支出在美国，强调了疾病的影响和流行1,7 .Nosocomial收购尿路感染主要与外国机构，如留置导尿管的存在有关。导管相关尿路感染（CAUTI）仍然获得尿路感染最常见的院内，占〜这种感染8的70-80％。此外，CAUTI与增加的发病率和死亡率相关联，并且它是次要血流感染9的最常见原因。 尿路感染收购相关的统一企业社会被认为是由通过机械操纵引进细菌进入膀胱从水库在胃肠道性交，卫生条件差或不同主机之间的其它微生物种群动态过程中造成的生态位10。一旦膀胱内，UPEC雇用许多毒力因子，包括胶囊，铁采集系统，毒素，毒力质粒的tRNA，致病岛和已被证明在发病中发挥作用定居因子&lt;SUP&gt; 11-14。关键要建立UPEC殖民化，统一企业也编码多种类型的胶粘剂伴侣迎来通路（CUP）菌毛识别受体的特异性立体15。 1型菌毛，放倒与FimH粘附，是由统一企业表达并结合甘露糖基uroplakins 16和α-1，β-3整联17，其被表达在人和小鼠囊18的腔表面。这些FimH介导的互动有利于细菌的定植和入侵的浅表上皮细胞19,20。一旦进入细胞，UPEC可以逃逸到细胞质其中单个细菌可以快速分裂，以形成细胞内细菌群落（IBC），其在成熟化，可以含有约10 4细菌21。 IBC形成已被证明在至少六个不同的小鼠品系，C3H / HeN系，C3H / HeJ小鼠，C57BL / 6，CBA，FVB / NJ和BALB / c，和与多种不同UPE的ç株和其他肠杆菌科22-24。然而IBC形成时空差异可以根据鼠标背景和感染UPEC应变而变化。在C3H /感染的典型UPEC HeN小鼠品系UTI89或CFT073，IBC形成可以早在3 HPI（小时后感染）可视化细菌的生物量小。该社区的不断扩大和达到的发展约6 HPI一个"中点"当棒状细菌占据终末分化肤浅伞细胞的细胞质空间的大百分比这些早期中型散货形式与显示类似的尺寸多数相对同步的方式和形态。 〜8 HPI的细菌从一个杆菌IBC变化球菌形态。中型散货箱是一过性的。因此，从12-18 HPI导致细菌群体的不断扩大IBC成熟，其次是他们的成丝和扩散出细胞的Wi随后日蔓延到相邻小区23。因此，IBC利基允许快速的细菌生长在从宿主免疫应答和抗生素25保护的环境。被UPEC感染所看到小鼠不同的阶段也观察到在人中，如中型散货和成丝，支持尿路感染的小鼠模型，可用于模拟UTI在人类22,26-28一个有益的工具。 虽然大多数女性体验UTI在其一生中，这些感染的结果可以从急性自限性感染无复发，频繁复发膀胱炎。此外，研究表明UTI强烈家族性发生，这表明遗传成分有助于UTI易感性29。我们已发现，看到在诊所的不同的UTI结果可以通过实验UPEC感染之间的近交小鼠品系30的不同的结果进行镜像。例如，C3H /母鸡，CBA，DBA和C3H / HeOuJ小鼠易感，在感染性剂量依赖性方式，以持久，慢性膀胱炎特征在于持久性，高滴度菌（&gt; 10 4集落形成单位（CFU）/ ml）的高滴度细菌膀胱负担在牺牲&gt;后4周感染（WPI），慢性炎症，和尿路上皮坏死。这些小鼠也显示，IL-6，G-CSF，KC，和IL-5的前24 HPI内升高的血清水平是作为生物标志物用于治疗慢性膀胱炎的发展。这可准确地表示UTI的自然过程在一些妇女，作为安慰剂的研究表明，妇女经历后膀胱炎的最初症状的UTI将保留在他们的尿高水平细菌数周的大百分比，如果不给予抗生素治疗31 32。此外，使用C3H / HeN小鼠中，我们发现，慢性膀胱炎的历史是用于随后的严重反复感染一个显著危险因素。复发性尿路感染是最SIUTI和C3H /纯鼠标gnificant临床表现是目前唯一研究模式，概括先前曝光后增加的倾向。第二UTI结局概括在C57BL / 6小鼠急性那里感染统一企业是自限性，与膀胱炎和菌大约在一个星期内解决。有趣的是，在这种模式下，UPEC容易形成内膀胱组织静止的细胞内储从中UPEC能够从休眠状态出现重新发起活性UTI，可能解释一种机制用于 ​​同一菌株复发性尿路感染在人中33,34。 除了上尿路感染易感性的遗传影响，引入导管插入膀胱大大增加具有感染以及增加的细菌能够引起感染的范围的可能性。已经证实，人类导尿引起组织学和由于机械应力，结果在一个健壮的炎症反应，剥脱，固有层和submucusa，尿路上皮变薄的水肿，尿路上皮和肾脏35,36的粘膜损伤的免疫学变化膀胱。此外，该导管提供用于细菌附着从而产生由几个物种用来使CAUTI的环境中的表面。而统一企业仍然是一个主要因素， 粪肠球菌占这些CAUTI 37的15％。E.粪变得对抗生素耐药越来越具有耐万古霉素的出现，构成了严重的健康问题38。E.肠球菌具有许多毒力因子，包括毒素和必要的附件二者导管和上皮38粘附。期间导尿，宿主是易受微生物附着，繁殖和传播，在泌尿道39,40。E. faeca利斯形成在导管生物膜作为一个机构的一部分，以坚持在膀胱和传播对肾脏，这是再生在小鼠CAUTI模型41。最近，已经在导尿所示，纤维蛋白原（纤维蛋白原）被释放到膀胱的炎症反应的一部分。蛋白原积聚在膀胱，大衣的导管，是必需成分为E.粪肠球菌生物膜的形成，运作作为附件支架。在CAUTI的C57BL / 6小鼠模型中，我们发现， 大肠杆菌肠球菌生物膜形成的导管，并因此持久性膀胱，是依赖于EBP菌毛 ​​，特别是其前端粘附EBPA。我们发现，EBPA的N-末端结构域特异性结合FG涂覆导管。此外，人们发现， 大肠杆菌利用粪作为纤维蛋白原期间感染源 ​​代谢产物，从而提高生物膜形成42。 小鼠模型已经证明关键understanding以及预测和UTI 41 CAUTI临床表现。在这篇文章中，我们证明接种物制备的膀胱炎UPEC的隔离UTI89和经尿道接种C3H / HeN小鼠的。此外，我们展示了一个协议，用于导管插入大肠杆菌的C57BL / 6小鼠和接种OG1RF 粪应变。这两种技术导致一致的和可靠的UTI或CAUTI小鼠。我们还显示用于急性膀胱炎和尿液收集用于治疗慢性或复发性膀胱炎的分析，观察IBC形成技术。 C3H / HeN小鼠已被用于研究统一企业发病机制方面，包括最初的细菌的入侵，形成IBC，成丝和慢性膀胱炎23,33,43的发展。这些毒力参数也已研究了在各种其他小鼠背景22,33。对于CAUTI的C57BL / 6模型允许异物植入，随后细菌共同膀胱电离，从而可以维持7天感染后41。这些模型已经用于评估细菌毒力机制，宿主对尿路感染和机制，以颠覆宿主反应，其中大部分已被随后概括或临床人群中观察到的有用。

<table><tbody><tr><td>Material for catheter and needle preparation:</td><td></td><td></td><td></td></tr><tr><td>30 G needles</td><td>BD Precision Glide</td><td>305106</td><td>30 G x &amp;frac12; (0.3 mm x 13 mm)</td></tr><tr><td>PE10 polyethylene tubing</td><td>BD</td><td>427400</td><td>Inside diameter -0.011 in (0.28 mm); outside diameter &amp;ndash; 0.024 in (0.61 mm)</td></tr><tr><td>RenaSIL 025 platinum cured silicon tubing</td><td>Braintree Scientific, Inc</td><td>SIL 025</td><td>inside diameter-0.012 x outside diameter 0.025, 25 ft coil</td></tr><tr><td colspan="4">Material for infections:</td></tr><tr><td>Isoflourane &amp;ndash; Isothesia</td><td>Butler Schein</td><td>29405</td><td>250 ml</td></tr><tr><td>Clear Glass Straight-Sided Jar</td><td>Kimble Chase</td><td>5413289V 21</td><td></td></tr><tr><td>Stainless Steel Tea Infuser</td><td>Schefs-Amazon</td><td></td><td>Premium Loose Leaf Tea Infuser By Schefs - Stainless Steel - Large Capacity -</td></tr><tr><td>Non-sterile cotton balls</td><td>Fisherbrand</td><td>22-456-880</td><td></td></tr><tr><td>50 ml Falcon tubes</td><td>VWR</td><td>89039-660</td><td></td></tr><tr><td>Isotec 3 -vaporizer</td><td>Ohmeda</td><td>1224478</td><td></td></tr><tr><td>Ear punch</td><td>Fisher Scientific</td><td>13-812-201</td><td>(when necessary)</td></tr><tr><td>Betadine solution</td><td>Betadine solution</td><td></td><td>10% Povidie-iodine topical solution</td></tr><tr><td>Q-tips</td><td>Fisher Scientific</td><td>22-037-924</td><td>6 inches</td></tr><tr><td>Diapers for bench</td><td>Fisherbrand</td><td>14206 63</td><td>Absorbent Underpads (20&amp;rdquo;X36&amp;rdquo;mats)</td></tr><tr><td>Surgical lubricant</td><td>Surgilube</td><td>0281-0205-36</td><td></td></tr><tr><td>Dissecting scissor</td><td>Fine Science tools, INC</td><td>14084-08</td><td></td></tr><tr><td>Micro-Adson Forceps</td><td>Fine Science tools, INC</td><td>11018-12</td><td></td></tr><tr><td>1 ml syringe</td><td>BD</td><td>309659</td><td>Tuberculin slip tip</td></tr><tr><td>Parafilm</td><td>Bemis</td><td>PM996</td><td>4 inches x 125 FT</td></tr><tr><td>Eppendorf rack</td><td>Fisherbrand</td><td>05-541-1</td><td></td></tr><tr><td>Eppendorf tubes</td><td>MIDSCI</td><td>AVX-T-17-C</td><td></td></tr><tr><td colspan="4">Harvesting catheters, bladders and kidneys:</td></tr><tr><td>Homogenizer</td><td>PRO Scientific INC</td><td>Bio-Gen Pro 200</td><td></td></tr><tr><td>5 ml polypropylene round-bottom tube</td><td>BD</td><td>352063</td><td>for organ homogenization</td></tr><tr><td>Paper towel</td><td>Georgia-Pacific</td><td></td><td></td></tr><tr><td>Ethanol</td><td>Pharmco-AAPER</td><td>11100020S</td><td>200 proof</td></tr><tr><td>Costar&amp;trade; Clear Polystyrene 96-Well Plates</td><td>Corning</td><td>3788</td><td></td></tr><tr><td>1x Phosphate sodium saline</td><td>Sigma-Aldrich</td><td>P3813</td><td></td></tr><tr><td>BRANSONIC Ultrasonic cleaner 1210</td><td>Branson Ultrasonics Corporation</td><td>1210</td><td></td></tr><tr><td colspan="4">IBC materials:</td></tr><tr><td>6-well tissue culture test plate</td><td>Techno Plastic Products</td><td>92006</td><td></td></tr><tr><td>Pins</td><td>Fine Science Tools</td><td>26002-20</td><td></td></tr><tr><td>Sylgard 184</td><td>Dow Corning</td><td>3097358-1004</td><td>Silicone Elastomer Kit</td></tr><tr><td>X-gal (5-bromo-4-chloro-3-indolyl-b-D-galactoside)</td><td>Invitrogen</td><td>15520-034</td><td>Ultrapure</td></tr><tr><td>N, N-Dimethylformamide</td><td>Sigma Aldrich</td><td>D4551</td><td></td></tr><tr><td>MgCl&lt;sub&gt;2&lt;/sub&gt; (Magnesium chloride)</td><td>Sigma Aldrich</td><td>M8266</td><td></td></tr><tr><td>Sodium deoxycholate</td><td>Sigma Aldrich</td><td>D6750</td><td></td></tr><tr><td>Nonidet-P40</td><td>Roche</td><td>11754599001</td><td>Octylphenolpoly(ethyleneglycolether)n</td></tr><tr><td>Potassium hexacyanoferrate(II) trihydrate (K-ferrOcyanide)</td><td>Sigma Aldrich</td><td>P3289</td><td></td></tr><tr><td>Potassium hexacyanoferrate(III) (K-ferrIcyanide)</td><td>Sigma Aldrich</td><td>60299</td><td></td></tr></tbody></table>

establishment and characterization of uti and cauti in a mouse model

尿路感染（UTI）是非常普遍的，发病的一个显著原因，并且是对治疗日益耐抗生素。女性不成比例地被折磨UTI:所有妇女的50％将在其一生中的UTI。此外，这些妇女谁有一个初步的UTI将遭受复发与一些患有复发频繁，在生活，疼痛和不适，日常活动中断的质量严重恶化的20-40％，医疗费用增加，以及一些治疗方案等较长期抗生素预防。尿路致病性大肠杆菌 （统一企业）是社区获得性尿路感染的主要病原体。导管相关UTI（CAUTI）是最常见的医院获得性感染占一百万出现在每年美国和戏剧性的医疗费用。而统一企业也是CAUTI的首要原因，其他病原体是增加的意义，包括肠球菌粪。在这里，我们利用这一概括许多这些人类疾病的临床特点两个成熟的小鼠模型。对于尿路感染，一个C3H /纯模式概括了许多致病统一企业在包括人类宿主反应，IBC的形成和丝状观察到的特征。对于CAUTI，使用C57BL / 6小鼠，其保留导管膀胱植入一个模型，已被证明是容易受到与粪膀胱感染。这些代表车型被用来获得惊人的新的见解尿路感染的发病机制，这是导致新的治疗和管理或预防战略。

简单和导管相关UTI的膀胱内的模型提供了灵活的平台，阐明细菌发病机理，宿主组织上这些疾病的影响，以及发展和新的方法测试的分子机制来管理这些常见和昂贵的感染。根据小鼠品系和病原体，膀胱内接种可用于研究宿主-病原体相互作用阐明必要用于发起或调节急性因素（ 图1和3），慢性或复发性（ 图2）膀胱炎。在图1中所示的数据是代表?...

Watch this Scientific Journal Video about Establishment and Characterization of UTI and CAUTI in a Mouse Model at JoVE.com

Establishment and Characterization of UTI and CAUTI in a Mouse Model

The ability to model urinary tract infections (UTI) is crucial in order to be able to understand bacterial pathogenesis and spawn the development of novel therapeutics. This work&#8217;s goal is to demonstrate mouse models of experimental UTI and catheter associated UTI that recapitulate and predict findings seen in humans.

建立和UTI和CAUTI表征在小鼠模型

Urinary tract infections (UTI) are highly prevalent, a significant cause of morbidity and are increasingly resistant to treatment with antibiotics. ...

establishment-and-characterization-of-uti-and-cauti-in-a-mouse-model

Research

JoVE Journal

Medicine

19.9K 次观看.  Washington University School of Medicine. The ability to model urinary tract infections (UTI) is crucial in order to be able to understand bacterial pathogenesis and spawn the development of novel therapeutics. This work’s goal is to demonstrate mouse models of experimental UTI and catheter associated UTI that recapitulate and predict findings seen in humans.

视频: Establishment and Characterization of UTI and CAUTI in a Mouse Model

Transurethral Induction of Mouse Urinary Tract Infection

Uropathogenic bacterial strains of interest are grown on agar. Generally, uropathogenic E. coli (UPEC) and other strains can be grown overnight on Luria-Bertani (LB) agar at 37&deg;C in ambient air. UPEC strains grow as yellowish-white translucent colonies on LB agar. Following confirmation of appropriate colony morphology, single colonies are then picked to be cultured in broth. LB broth can be used for most uropathogenic bacterial strains. Two serial, overnight LB broth cultures can be employed to enhance expression of type I pili, a well-defined virulence factor for uropathogenic bacteria. Broth cultures are diluted to the desired concentration in phosphate buffered saline (PBS). Eight to 12 week old female mice are placed under isoflurane anesthesia and transurethrally inoculated with bacteria using polyethylene tubing-covered 30 gauge syringes. Typical inocula, which must be empirically determined for each bacterial/mouse strain combination, are 106 to 108 cfu per mouse in 10 to 50 microliters of PBS. After the desired infection period (one day to several weeks), urine samples and the bladder and both kidneys are harvested. Each organ is minced, placed in PBS, and homogenized in a Blue Bullet homogenizer. Urine and tissue homogenates are serially diluted in PBS and cultured on appropriate agar. The following day, colony forming units are counted.

This video will demonstrate methods to transurethrally induce mouse urinary tract infections and quantify the extent of resulting infections.

经尿道诱导小鼠尿路感染

Uropathogenic bacterial strains of interest are grown on agar. Generally, uropathogenic E. coli (UPEC) and other strains can be grown overnight on ...

科研

免疫与感染

A Mouse Model of in Utero Transplantation

The transplantation of stem cells and viruses in utero has tremendous potential for treating congenital disorders in the human fetus. For example, in utero transplantation (IUT) of hematopoietic stem cells has been used to successfully treat patients with severe combined immunodeficiency.1,2 In several other conditions, however, IUT has been attempted without success.3 Given these mixed results, the availability of an efficient non-human model to study the biological sequelae of stem cell transplantation and gene therapy is critical to advance this field. We and others have used the mouse model of IUT to study factors affecting successful engraftment of in utero transplanted hematopoietic stem cells in both wild-type mice4-7 and those with genetic diseases.8,9 The fetal environment also offers considerable advantages for the success of in utero gene therapy. For example, the delivery of adenoviral10, adeno-associated viral10, retroviral11, and lentiviral vectors12,13 into the fetus has resulted in the transduction of multiple organs distant from the site of injection with long-term gene expression. in utero gene therapy may therefore be considered as a possible treatment strategy for single gene disorders such as muscular dystrophy or cystic fibrosis. Another potential advantage of IUT is the ability to induce immune tolerance to a specific antigen. As seen in mice with hemophilia, the introduction of Factor IX early in development results in tolerance to this protein.14 
In addition to its use in investigating potential human therapies, the mouse model of IUT can be a powerful tool to study basic questions in developmental and stem cell biology. For example, one can deliver various small molecules to induce or inhibit specific gene expression at defined gestational stages and manipulate developmental pathways. The impact of these alterations can be assessed at various timepoints after the initial transplantation. Furthermore, one can transplant pluripotent or lineage specific progenitor cells into the fetal environment to study stem cell differentiation in a non-irradiated and unperturbed host environment.
The mouse model of IUT has already provided numerous insights within the fields of immunology, and developmental and stem cell biology. In this video-based protocol, we describe a step-by-step approach to performing IUT in mouse fetuses and outline the critical steps and potential pitfalls of this technique.

A Mouse Model of in Utero Transplantation

The mouse model of in utero transplantation is a versatile tool that can be used to study the potential clinical applications of stem cell transplantation and gene therapy in the fetus. In this protocol, we present a general approach to performing this technique

一个小鼠模型在子宫内移植

The transplantation of stem cells and viruses in utero has tremendous potential for treating congenital disorders in the human fetus.  For example, in ...

医学

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma

Loco-regional invasion of head and neck cancer is linked to metastatic risk and presents a difficult challenge in designing and implementing patient management strategies. Orthotopic mouse models of oral cancer have been developed to facilitate the study of factors that impact invasion and serve as model system for evaluating anti-tumor therapeutics. In these systems, visualization of disseminated tumor cells within oral cavity tissues has typically been conducted by either conventional histology or with in vivo bioluminescent methods. A primary drawback of these techniques is the inherent inability to accurately visualize and quantify early tumor cell invasion arising from the primary site in three dimensions. Here we describe a protocol that combines an established model for squamous cell carcinoma of the tongue (SCOT) with two-photon imaging to allow multi-vectorial visualization of lingual tumor spread. The OSC-19 head and neck tumor cell line was stably engineered to express the F-actin binding peptide LifeAct fused to the mCherry fluorescent protein (LifeAct-mCherry). Fox1nu/nu mice injected with these cells reliably form tumors that allow the tongue to be visualized by ex-vivo application of two-photon microscopy. This technique allows for the orthotopic visualization of the tumor mass and locally invading cells in excised tongues without disruption of the regional tumor microenvironment. In addition, this system allows for the quantification of tumor cell invasion by calculating distances that invaded cells move from the primary tumor site. Overall this procedure provides an enhanced model system for analyzing factors that contribute to SCOT invasion and therapeutic treatments tailored to prevent local invasion and distant metastatic spread. This method also has the potential to be ultimately combined with other imaging modalities in an in vivo setting.

A comprehensive overview of the techniques involved in generating a mouse model of oral cancer and quantitative monitoring of tumor invasion within the tongue through multi-photon microscopy of labeled cells is presented. This system can serve as a useful platform for the molecular assessment and drug efficacy of anti-invasive compounds.

多光子成像在口腔鳞状细胞癌原位小鼠模型的肿瘤细胞的侵袭

Loco-regional invasion of head and neck cancer is linked to metastatic risk and presents a difficult challenge in designing and implementing patient ...

Establishment of Human Epithelial Enteroids and Colonoids from Whole Tissue and Biopsy

The epithelium of the gastrointestinal tract is constantly renewed as it turns over. This process is triggered by the proliferation of intestinal stem cells (ISCs) and progeny that progressively migrate and differentiate toward the tip of the villi. These processes, essential for gastrointestinal homeostasis, have been extensively studied using multiple approaches. Ex vivo technologies, especially primary cell cultures have proven to be promising for understanding intestinal epithelial functions. A long-term primary culture system for mouse intestinal crypts has been established to generate 3-dimensional epithelial organoids. These epithelial structures contain crypt- and villus-like domains reminiscent of normal gut epithelium. Commonly, termed &#8220;enteroids&#8221; when derived from small intestine and &#8220;colonoids&#8221; when derived from colon, they are different from organoids that also contain mesenchyme tissue. Additionally, these enteroids/colonoids continuously produce all cell types found normally within the intestinal epithelium. This in vitro organ-like culture system is rapidly becoming the new gold standard for investigation of intestinal stem cell biology and epithelial cell physiology. This technology has been recently transferred to the study of human gut. The establishment of human derived epithelial enteroids and colonoids from small intestine and colon has been possible through the utilization of specific culture media that allow their growth and maintenance over time. Here, we describe a method to establish a small intestinal and colon crypt-derived system from human whole tissue or biopsies. We emphasize the culture modalities that are essential for the successful growth and maintenance of human enteroids and colonoids.

We describe a method to establish human enteroids from small intestinal crypts and colonoids from colon crypts collected from both surgical tissue and biopsies. In this methodological article, we present the culture modalities that are essential for the successful growth and maintenance of human enteroids and colonoids.

从整体组织和活检建立人类上皮Enteroids和Colonoids的

The epithelium of the gastrointestinal tract is constantly renewed as it turns over. This process is triggered by the proliferation of intestinal stem ...

Urinary Tract Infection in a Small Animal Model: Transurethral Catheterization of Male and Female Mice

Urinary tract infections (UTI) are extremely common worldwide, incurring significant morbidity and healthcare-associated expenses. Small animal models, which accurately reflect disease establishment and progression, permit dissection of host-pathogen interactions and generation of immunity to infection. In mice, intravesical instillation of uropathogenic E. coli, the causative agent in more than 85% of community acquired UTI, recapitulates many of the stages of infection observed in humans. Until recently, however, UTI could only be modeled in female animals. This limitation has hindered the study of sex-related differences in UTI, as well as other bladder pathologies, such as cancer. Here, we describe a method to instill male mice that allows direct comparison between female and male animals and provide a detailed protocol to assess bladder tissue by flow cytometry as a means to better understand host responses to infection. Together, these approaches will aid in the identification of host factors that contribute to sex biases observed in UTI and other bladder-associated diseases.

The established model of transurethral catheterization of mice allows the study of bladder pathologies, including urinary tract infection, but can only be performed in females. A new model of male transurethral instillation, presented here, will enable research in an area marked by strong clinical and epidemiological differences between the sexes.

小动物模型尿路感染的实验研究: 男性和女性的经尿道插管

Urinary tract infections (UTI) are extremely common worldwide, incurring significant morbidity and healthcare-associated expenses. Small animal models, ...

Recurrent Escherichia coli Urinary Tract Infection Triggered by Gardnerella vaginalis Bladder Exposure in Mice

Recurrent urinary tract infections (rUTI) caused by uropathogenic Escherichia coli (UPEC) are common and costly. Previous articles describing models of UTI in male and female mice have illustrated the procedures for bacterial inoculation and enumeration in urine and tissues. During an initial bladder infection in C57BL/6 mice, UPEC establish latent reservoirs inside bladder epithelial cells that persist following clearance of UPEC bacteriuria. This model builds on these studies to examine rUTI caused by the emergence of UPEC from within latent bladder reservoirs. The urogenital bacterium Gardnerella vaginalis is used as the trigger of rUTI in this model because it is frequently present in the urogenital tracts of women, especially in the context of vaginal dysbiosis that has been associated with UTI. In addition, a method for in situ bladder fixation followed by scanning electron microscopy (SEM) analysis of bladder tissue is also described, with potential application to other studies involving the bladder.

Recurrent Escherichia coli Urinary Tract Infection Triggered by Gardnerella vaginalis Bladder Exposure in Mice

A mouse model of uropathogenic E. coli (UPEC) transurethral inoculation to establish latent intracellular bladder reservoirs and subsequent bladder exposure to G. vaginalis to induce recurrent UPEC UTI is demonstrated. Also demonstrated are the enumeration of bacteria, urine cytology, and in situ bladder fixation and processing for scanning electron microscopy.

由加德纳菌阴道膀胱暴露在小鼠中引发的复发性大肠杆菌尿路感染

Recurrent urinary tract infections (rUTI) caused by uropathogenic Escherichia coli (UPEC) are common and costly. Previous articles describing models of ...

Longitudinal Follow-Up of Urinary Tract Infections and Their Treatment in Mice using Bioluminescence Imaging

Urinary tract infections (UTI) rank among the most common bacterial infections in humans and are routinely treated with empirical antibiotics. However, due to increasing microbial resistance, the efficacy of the most used antibiotics has declined. To find alternative treatment options, there is a great need for a better understanding of the UTI pathogenesis and the mechanisms that determine UTI susceptibility. In order to investigate this in an animal model, a reproducible, non-invasive assay to study the course of UTI is indispensable.
For years, the gold standard for the enumeration of bacterial load has been the determination of Colony Forming Units (CFU) for a particular sample volume. This technique requires post-mortem organ homogenates and serial dilutions, limiting data output and reproducibility. As an alternative, bioluminescence imaging (BLI) is gaining popularity to determine the bacterial load. Labeling pathogens with a lux operon allow for the sensitive detection and quantification in a non-invasive manner, thereby enabling longitudinal follow-up. So far, the adoption of BLI in UTI research remains limited.
This manuscript describes the practical implementation of BLI in a mouse urinary tract infection model. Here, a step-by-step guide for culturing bacteria, intravesical instillation and imaging is provided. The in vivo correlation with CFU is examined and a proof-of-concept is provided by comparing the bacterial load of untreated infected animals with antibiotic-treated animals. Furthermore, the advantages, limitations, and considerations specific to the implementation of BLI in an in vivo UTI model are discussed. The implementation of BLI in the UTI research field will greatly facilitate research on the pathogenesis of UTI and the discovery of new ways to prevent and treat UTI.

This manuscript describes the intravesical administration of uropathogenic bacteria with a lux operon to induce a urinary tract infection in mice and subsequent longitudinal in vivo analysis of the bacterial load using bioluminescence imaging.

使用生物发光成像对小鼠尿路感染及其治疗的纵向随访

Urinary tract infections (UTI) rank among the most common bacterial infections in humans and are routinely treated with empirical antibiotics. However, ...

Transurethral Catheterization and Bacterial Inoculation to Generate a Urinary Tract Infection Model in Male Mice

Source: Zychlinsky Scharff, A., et al. <a href="https://app.jove.com/v/54432">Urinary Tract Infection in a Small Animal Model: Transurethral Catheterization of Male and Female Mice.</a> J. Vis. Exp. (2017).
This video demonstrates the establishment of uropathogenic Escherichia coli infection in a female mouse bladder through transurethral catheter instillation. The injected bacteria successfully establish a urinary tract infection within the bladder, providing a valuable platform for studying healthcare-associated diseases related to the urinary tract.

经尿道导管插入术和细菌接种在雄性小鼠中生成尿路感染模型

All procedures involving animal models have been reviewed by the local institutional animal care committee and the JoVE veterinary review board.
1. ...

JoVE Encyclopedia of Experiments

Immunology

Immunopathology

Host-Pathogen Interaction Models

Establishment of a Urinary Tract Infection Model in Female Mice

Source: Zychlinsky Scharff, A. et al., <a href="https://app.jove.com/v/54432">Urinary Tract Infection in a Small Animal Model: Transurethral Catheterization of Male and Female Mice.</a>&#160;J. Vis. Exp. (2017)
This video demonstrates the establishment of uropathogenic Escherichia coli infection in a female mouse bladder through transurethral catheter instillation. The injected bacteria successfully establish a urinary tract infection within the bladder, providing a valuable platform for studying healthcare-associated diseases related to the urinary tract.

雌性小鼠尿路感染模型的建立

Generating Urinary Tract Infection Model: A Technique to Administer Uropathogenic Bacteria in Mouse to Develop Urinary Tract Infection Model

Source: Luyts, N. et al., <a href="https://www.jove.com/v/62614">Longitudinal Follow-Up of Urinary Tract Infections and Their Treatment in Mice using Bioluminescence Imaging.</a> J. Vis. Exp. (2021).
In this video, we describe the technique for the intravesical administration of uropathogenic bacteria to generate a urinary tract infection model in mice. This model can be used to understand the spread of uropathogenic bacterial infection within the urinary system and the mechanisms that determine UTI susceptibility.

生成尿路感染模型:一种在小鼠中施用尿路致病菌以开发尿路感染模型的技术

Source: Luyts, N. et al., Longitudinal Follow-Up of Urinary Tract Infections and Their Treatment in Mice using Bioluminescence Imaging. J. Vis. Exp. ...